Our CEO Francois-Thomas Michaud and Strategic Alliance Director, Vincent Ménard, MBA Ph.D. will be attending RESI2018 conference in Toronto, April 10th. Come and meet with them to discuss how Feldan Therapeutics could be a strong investment opportunity. http://www.resiconference.com/
QUÉBEC city, March 29, 2018 – CQDM is pleased to announce the selection of a new Quantum Leap project jointly with Feldan Therapeutics for a total amount of $1.2M. The funds will be used for further development of a breakthrough drug delivery technology, in collaboration with Professor Frédéric Calon from Laval University. CQDM’s support for this
Feldan Therapeutics will be attending the Innate Killer Summit from March 27 to 29 in San Diego, CA, USA. Come and meet with our Business Development Director Meriem Benchabane and one of our scientist, Mario Harvey. Discover the Feldan Shuttle, a protein-based technology platform that directly delivers proteins – such as nucleases or transcription factors – inside cells to
Combined Feldan Shuttle and Green Cross LabCell NK cell technologies will be used to develop hyperactive NK cell immunotherapies QUEBEC, Jan. 15, 2018 /CNW Telbec/ – Green Cross LabCell, involved in development of next generation biologics, and Feldan Therapeutics, focused on intracellular delivery of proteins, today announced a joint
QUEBEC CITY, Aug. 22, 2017 – Feldan Therapeutics, Inc. today announced the issuance of its first patent covering the company’s technology, the Feldan Shuttle platform. The United States Patent and Trademark Office (USPTO) granted Feldan Therapeutics the patent on August 22nd, 2017. The Feldan Shuttle platform is a peptide-based delivery method that allows the introduction of foreign
Feldan Therapeutics will be attending the BIO International Convention 2017 June 19-22, 2017 in San Diego, CA. We are excited to be part in this even again this year! Our team would be happy to meet you there!
Feldan Therapeutics and Elasmogen Announce Research Agreement with Amgen to Develop Intracellular Biologics Combined Feldan Shuttle and Elasmogen soloMER technology will be used to deliver intracellular candidates for two targets Aberdeen, Scotland and Quebec City, Canada; 9 May 2017: Elasmogen Ltd, focused on the development of next generation biologics, and Feldan Therapeutics, focused on intracellular delivery of proteins, today announce
2017 Tous droits réservés | Feldan | Encore une bonne Id !